![Martine Zimmermann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martine Zimmermann
Directeur/Bestuurslid bij INVENTIVA
Vermogen: 298 028 $ op 30-06-2024
Actieve functies van Martine Zimmermann
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
INVENTIVA | Directeur/Bestuurslid | 16-04-2021 | - |
Independent Dir/Board Member | 16-04-2021 | - | |
LIGAND PHARMACEUTICALS INCORPORATED | Directeur/Bestuurslid | 26-09-2023 | - |
Independent Dir/Board Member | 26-09-2023 | - | |
Ipsen Biopharmaceuticals, Inc. | Algemeen Adviseur | - | - |
Loopbaan van Martine Zimmermann
Eerdere bekende functies van Martine Zimmermann
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Algemeen Adviseur | 01-06-2016 | 01-02-2023 |
Caelum Biosciences, Inc.
![]() Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Directeur/Bestuurslid | 01-03-2019 | 01-01-2021 |
Opleiding van Martine Zimmermann
Louis Pasteur University | Doctorate Degree |
University of Strasbourg | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Frankrijk | 4 |
Operationeel
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
General Counsel | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
INVENTIVA | Health Technology |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Caelum Biosciences, Inc.
![]() Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
Ipsen Biopharmaceuticals, Inc. |
- Beurs
- Insiders
- Martine Zimmermann
- Ervaring